Macrolide-resistant Streptococcus pyogenes isolates from Finland, Australia, and the United Kingdom and, more recently, Streptococcus pneumoniae and S. pyogenes strains from the United States were shown to have an unusual resistance pattern to macrolides, lincosamides, and streptogramin B antibiotics. This pattern, referred to as M resistance, consists of susceptibility to clindamycin and streptogramin B antibiotics but resistance to 14-and 15-membered macrolides. An evaluation of the macrolide-lincosamide-streptogramin B resistance phenotypes among our streptococcal strains collected from 1993 to 1995 suggested that this unusual resistance pattern is not rare. Eighty-five percent (n ‫؍‬ 66) of the S. pneumoniae and 75% (n ‫؍‬ 28) of the S. pyogenes strains in our collection had an M phenotype. The mechanism of M resistance was not mediated by target modification, as isolated ribosomes from a pneumococcal strain bearing the M phenotype were fully sensitive to erythromycin. Further, the presence of an erm methylase was excluded with primers specific for an erm consensus sequence. However, results of studies that determined the uptake and incorporation of radiolabeled erythromycin into cells were consistent with the presence of a macrolide efflux determinant. The putative efflux determinant in streptococci seems to be distinct from the multicomponent macrolide efflux system in coagulase-negative staphylococci. The recognition of the prevalence of the M phenotype in streptococci has implications for sensitivity testing and may have an impact on the choice of antibiotic therapy in clinical practice.
There are presently three recognized mechanisms of resistance to macrolide antibiotics: target modification, inactivation, and efflux (36) (37) (38) 72) . Target modification occurs at the level of the ribosomes via an erm gene encoding a 23S rRNA methylase (36, 38, 72) . There are currently at least eight classes of erm genes distinguishable by hybridization criteria (36, 38, 72) . Erm methylases add either one or two methyl residues to a highly conserved adenine residue in domain V, the peptidyl transferase center, of 23S rRNA (33, 72) . This modification renders the strain resistant to most macrolides, lincosamides, and streptogramin B compounds; phenotypically, this resistance pattern is known as MLS B resistance (21, 33) . Expression of MLS B resistance can be inducible or constitutive and is unrelated to the class of an erm determinant (10, 18, 36, 71, 73) . Regulation of the methylase depends upon the sequence of the regulatory domain upstream of the structural gene and is accounted for by a translational attenuation mechanism (10, 18, 36, 71, 73) .
Resistance to MLS antibiotics due to inactivation has been described for a number of clinically important organisms, including Staphylococcus aureus (12, 16, 35, 39, 40, 75) Staphylococcus haemolyticus (12, 35) , and Escherichia coli (1, 3, 4, 9, 31, (51) (52) (53) (54) . To our knowledge, no form of macrolide inactivation has been described for streptococci.
Staphylococci appear to have an efflux system (19, 28, 37, 42, 43, 46, (59) (60) (61) 75) with specificity for 14-and 15-membered macrolides and type B streptogramin molecules but not for lincosamide antibiotics (the MS phenotype). The efflux system appears to be multicomponent, involving msrA (60, 61) , smp (59) and/or stp (59) genes to constitute a fully operational efflux pump. msrA and stp genes encode ATP-binding proteins homologous to a superfamily of related proteins that contain two conserved ATP-binding sites that are involved in transport (27, 41, 49) , while smp genes encode a hydrophobic transmembrane protein, the putative pump. Presently, it is unclear what role each protein plays in the functional efflux system; however, it is clear that MsrA must be present to confer the macrolide and streptogramin B resistance (MS) phenotype (59) . Efflux has not been described for streptococci.
Macrolide resistance via an energy-dependent mtr efflux system in gonococci was recently reported (26, 55) . This efflux system, similar to the mexAB-oprK efflux system of Pseudomonas aeruginosa and the acrAB and acrEF efflux pumps of E. coli, is not specific for macrolides (49) . Rather, these pumps appear to be important for preventing entry of structurally diverse, but undesirable agents, thereby enhancing the survival of the organism in its ecological niche.
Clinical Streptococcus pyogenes strains from Finland (63, 64), Australia (67), the United Kingdom (58, 62, 77) , and North America (15) have been described with an M phenotype, that is, resistance to macrolides but susceptibility to lincosamide and streptogramin B antibiotics. A study of pneumococci recovered from middle ear and sinus cultures of children from Houston, Texas, noted isolates with an M phenotype (48) . Evaluation of our clinical streptococcal strains revealed that the majority of S. pyogenes and Streptococcus pneumoniae strains had an M phenotype. Our studies showed that the determinant responsible for the M phenotype appears to be distinct from known erm genes and is not mediated through target modification. Rather, we found that strains bearing the M phenotype contain an efflux system for erythromycin apparently distinct from the efflux system described for erythromycin-resistant staphylococci. [14] ) and 02C1062 (strain AC1 cured of plasmid pAC1 [14] ) were obtained from Don Clewell (University of Michigan); S. pneumoniae R6, an unencapsulated derivative of the Rockefeller University strain R36A (7), was obtained through the courtesy of Regine Hakenbeck (Max-Planck Institute, Berlin, Germany); S. pneumoniae 02J1047 (strain 13433 [8] ), an ermB strain, was obtained from A. Fremaux (Centre Hospitalier Intercommunal, Creteil, France); and S. pneumoniae 02J1016 (25) , an MLS B -susceptible serotype 3 strain, was obtained from J.-J. Pocidalo (Hôpital Claude Bernard, Paris, France).
Strain characterization. All strains were screened for MLS B resistance by an agar disk diffusion assay. Isolated colonies were selected by a BBL Prompt system (Becton Dickinson, Cockeysville, Md.). This standardized cell suspension served as an inoculum for streaking the surface of a blood agar plate. Clindamycin (2 g), erythromycin (15 g), and CP-37,277 (25 g) disks were placed on the plates approximately 12 mm apart. The plates were incubated overnight at 37ЊC in an atmosphere containing 5% carbon dioxide. Blunting of the zones around clindamycin or the streptogramin B analog (CP-37,277) indicated inducible resistance to these compounds (36, 38) , whereas constitutive resistance was indicated by no zones to clindamycin and CP-37277 and either a small zone or no zone to erythromycin.
Inactivation of radiolabeled erythromycin in concentrated cell suspensions was assessed as described previously (75, 76) .
Macrolide efflux by actively growing cells. Freshly grown colonies from blood agar plates were used to inoculate Todd-Hewitt broth for growth overnight in 5% CO 2 at 37ЊC. The overnight culture was diluted to an optical density at 650 nm (OD 650 ) of 0.1 and grown in 5% CO 2 without shaking until an OD 650 of 0.3 was reached. At this point, 0.02 g of erythromycin per ml was added to ensure full induction of the efflux determinant and the culture was incubated for another hour. [ 14 C]erythromycin was added at a final concentration of 0.2 g/ml, and uptake was assessed by removing aliquots of the culture in duplicate, filtering each sample onto prewet GF/C filters, and washing the filters twice with 0.9% NaCl containing 1 g of erythromycin per ml. The amount of radiolabeled erythromycin that is cell associated was determined after scintillation counting of the dried filters. In a typical experiment, the OD 650 from the addition of [ 14 C]erythromycin to the end of the experiment (45 min) increased by ϳ35%. Samples receiving 10 mM arsenate or 25 M CCCP were exposed to the drug for 10 min prior to the addition of radiolabeled erythromycin; no change in OD 650 was noted during the course of the experiment.
DNA isolation, PCR, and hybridization conditions. Total genomic DNA was isolated from streptococcal strains as described in reference 6, with slight modifications. For maximal lysis of S. pneumoniae, the period of proteinase K-sodium dodecyl sulfate (SDS) digestion at 37ЊC was increased to 3 h. To provide adequate DNA yields, group A streptococci were incubated with lysozyme (6 mg/ml) at 37ЊC for 1 h prior to the addition of proteinase K-SDS. For staphylococcal strains (controls), cell walls were digested with lysostaphin (50 g/ml for 1 h at 37ЊC) prior to the addition of proteinase K-SDS. The PCR reaction mixture was as recommended by Perkin-Elmer, with the concentration of magnesium being optimized for each primer set (4 mM for ermA and msrA-msrB primer sets and 2 mM for ermB, ermC, and consensus erm primer sets). DNA in the reaction mixture (20 l) was denatured at 93ЊC for 3 min and then annealed at 52ЊC. The amplification cycles consisted of elongation at 72ЊC for 60 s, denaturation at 93ЊC for 60 s, and annealing at 52ЊC for 60 s. After 35 amplification cycles, the last elongation step was performed at 72ЊC for 5 min. Primer sets specific for the detection of ermA, ermB, ermC, and msrA-msrB were as described previously (68, 75) . Primers for smp were based on the published sequence of smpA (59): 5Ј-AAATTGTTTAAAAAGAAATC-3Ј and 5Ј-TTTGAACCATAATATTCAT C-3Ј. These primers, when used on plasmid DNA isolated from Staphylococcus epidermidis S1187, produced the expected 616-bp PCR product. The smp probe was labeled with a digoxigenin DNA random prime DNA labelling and detection kit (Boehringer Mannheim) and hybridized to DNA on a Magnagraph nylon membrane (Micron Separations Inc., Westboro, Mass.) according to the manufacturer's instructions.
Isolation of S. pneumoniae ribosomes. S. pneumoniae strains R6 (susceptible) and 02J1175 (M phenotype; one of the strains from Kentucky from 1995) ( Table  1) were grown in 5% CO 2 overnight in Todd-Hewitt broth supplemented with 0.05% sodium thioglycolate and 2% neutralized yeast extract at 37ЊC. The overnight culture was used as an inoculum (20%) in 9 liters of the abovedescribed medium, and cells were harvested after 6 h of aerobic growth at 37ЊC. Cells were lysed in a 0.01 M Tris (pH 7.5) buffer containing 0.15 M NaCl, 0.01 M MgCl 2 , 0.35 M NH 4 Cl, 0.25% SDS, 1 g of DNase I per ml, and 0.25% sodium deoxycholate as described in the report of Swendsen and Johnson (69) . The ammonium sulfate precipitation procedure described by Fogel and Sypherd (22) was used to isolate the ribosomes. Isolated ribosomes from the pneumococci were reconstituted with an S150 extract from Staphylococcus aureus RN4220. Translation was monitored in vitro by a microtiter-based poly(A) system (75) .
RESULTS
Phenotypic analysis of streptococcal strains. By the agar disk diffusion assay, 66 erythromycin-resistant strains of S. pneumoniae and 28 erythromycin-resistant S. pyogenes strains were evaluated (Tables 1 and 2 ). Blunting of the zones around clindamycin or the streptogramin B analog (CP-37,277) indicated inducible resistance to these compounds (36, 38) , whereas constitutive resistance was indicated by either a small zone or no zone. As described by Seppälä et al. (64) , three different phenotypes were distinguishable for the group A isolates: constitutive MLS B resistance (cMLS B ), inducible MLS B resistance (iMLS B ), and a novel phenotype which we designate M. The M phenotype is typified by strains remaining susceptible to clindamycin and streptogramin B antibiotics while being resistant to 14-and 15-membered macrolides. The M phenotype was also found in our recent clinical isolates of pneumococci. To our surprise, the M phenotype constituted 75% of the erythromycin-resistant S. pyogenes isolates and 85% of the erythromycin-resistant S. pneumoniae isolates.
For this study, clinical laboratories were requested to send erythromycin-resistant S. pneumoniae and S. pyogenes strains. It is interesting that the vast majority of the pneumococci are also penicillin resistant (Pen r ) (76%) and that 52% of the Pen r isolates show high-level Pen r (MIC Ն 2 g/ml). The association of macrolide and penicillin resistance in S. pneumoniae has been noted by others (11, 29, 48, 74) . The 10 pneumococci with an MLS B -resistant phenotype were all coresistant to penicillin, while 71.4% of the isolates bearing an M phenotype were coresistant to penicillin. None of the S. pyogenes isolates were resistant to penicillin in vitro.
M strains do not have an erm methylase. Primer sets designed to specifically detect ermA, ermB, or ermC methylase revealed the presence of the archetypal ermB in all of the MLS B -resistant strains of S. pneumoniae (Table 1) . However, only one of seven MLS B -resistant strains of S. pyogenes gave a specific PCR product with the ermB-specific primers. With a set of degenerate primers (5) designed to detect ermA, ermB, ermC, ermG, and related variants, four of the seven strains were found to have an erm-type sequence (listed as variants in Table 2 because they were not detected with the archetypal ermB-specific primers). Interestingly, the two remaining MLS B -resistant strains of S. pyogenes did not give a specific PCR product even with the degenerate primers. The most likely explanation for erythromycin resistance in the strains labeled as having a variant erm is that the resident erm has a sequence slightly different from that region recognized by the ermB-specific primers. The two S. pyogenes strains that do not give a PCR product with the degenerate erm primer set may have an alteration in the peptidyl transferase center or some other unknown mechanism that confers coresistance to MLS B antibiotics. In an effort to address the former possible explanation, the copy number of 23S rRNA genes in S. pyogenes was investigated; six copies were found in both MLS B -susceptible and MLS B -resistant strains (data not shown). Others have found that organisms containing four or less 23S rRNA copies can be phenotypically MLS B resistant when only one of the rRNA genes contains a base change at the methylatable adenine (A-2058 [72] ) in the peptidyl transferase center (45, 57, 72) . In E. coli, with seven rRNA genes, a base change at A-2058 in only one of the gene copies is phenotypically recessive (72) . Given that S. pyogenes' copy number was close to seven, it seemed unlikely that MLS B resistance in these strains could be accounted for by an alteration in the rRNA sequence. However, future studies with these strains are necessary to determine if the determinant(s) is novel. Streptococcal strains bearing an M phenotype failed to yield a PCR product with any of the erm primer sets, including the consensus erm primers. To determine if these strains bear a target modification specific for macrolides, ribosomes were isolated from strain 02J1175, an S. pneumoniae strain with an M phenotype. Figure 1 compares the sensitivity of ribosomes isolated from 02J1175 to that of a well-known laboratory pneumococcal strain, R6, in a reconstituted translation assay. Ribosomes isolated from either strain are fully sensitive to the inhibition of either erythromycin or azithromycin (Fig. 1) . Thus, it appears that the determinant specifying erythromycin resistance in strain 02J1175 does not alter the binding of macrolides to the ribosome. (Attempts to isolate functional ribosomes from MLS B -resistant S. pneumoniae strains were unsuccessful, but ribosomes isolated from MLS B -resistant S. aureus cells have 50% inhibitory concentrations of Ͼ100 g/ml [75] .)
Streptococci with the M phenotype efflux erythromycin. Inactivation of erythromycin by clinical gram-positive strains has been described only for Staphylococcus aureus (75) . Although degradation was considered a mechanism that could account for the M phenotype, we found no evidence for inactivation of erythromycin by any of the S. pyogenes or S. pneumoniae strains in our culture collection (reference 76 and data not shown).
The M phenotype in streptococci is reminiscent of the MS phenotype (resistance to macrolide and streptogramin B antibiotics but susceptible to lincosamide antibiotics) described for staphylococci (19, 28, 34, 42, 43, 46, (59) (60) (61) 75) . To determine if resistance to macrolides is mediated by an efflux mechanism, exponentially growing cells of S. pyogenes and S. pneumoniae were evaluated for their uptake and incorporation of radiolabeled erythromycin in the absence or in the presence of CCCP or arsenate, agents that disrupt proton motive force. Figures 2  and 3 provide examples of erythromycin uptake by susceptible strains (02C1062 in Fig. 2 and R6 and 02J1016 in Fig. 3) , isolates with an M phenotype (02C1063 and 02C1064 in Fig. 2 and 02J1086 and 02J1088 in Fig. 3) , and control strains that are resistant to macrolides via an ermB methylase (strains 02C1061 and 02J1047 in Fig. 2 and 3, respectively) .
The initial rate of incorporation of erythromycin by susceptible streptococci is rapid, after which either a plateau phase (02J1062 in Fig. 2 and R6 in Fig. 3 ) or a slower rate of uptake (02J1016 in Fig. 3 ) occurs. Pretreatment with CCCP or arsenate did not greatly alter the accumulation in 02C1062 (Fig. 2) or 02J1016 (Fig. 3) , while a more substantial amount of erythromycin is evident in R6 following pretreatment with arsenate (Fig. 3) . The increased amount of uptake was noted in other susceptible strains of pneumococci (data not shown); a similar phenomenon has been eloquently explained by Nikaido and Thanassi (50) . The cytosolic total concentration of erythromycin is lower than that of the external medium because of the pH gradient (a major component of proton motive force). The addition of CCCP or arsenate collapses the pH gradient, producing an influx of erythromycin as a result of equilibration of free drug (50) .
Strains with an M phenotype do not maximally accumulate erythromycin (even after 30 to 45 min) unless they are pretreated with 25 M CCCP (Fig. 2) or 10 mM arsenate (Fig. 3) . The additional accumulation in these strains appears to result from the inhibition of a proton motive force-sensitive efflux pump. This interpretation is made in conjunction with the knowledge that these strains are erythromycin resistant. MICs observed for S. pneumoniae or S. pyogenes strains with an M phenotype are in the 4 to 16-g/ml range, distinguishable from MLS B -susceptible strains (MICs Յ 0.25 g/ml).
There is no substantial retention of radiolabeled erythromycin in MLS B -resistant strains; this is expected because ErmBmodified ribosomes can no longer bind erythromycin. Further, pretreatment of strains containing ErmB with CCCP or arsenate does not alter the small amount of erythromycin accumulated.
Macrolide efflux in M strains appears to be distinct. To determine if the efflux system in streptococci was distinct from the multicomponent efflux pump described for coagulase-negative staphylococci, strains with the M phenotype were probed with smpA from Staphylococcus epidermidis S1187 (59, 60) and evaluated by PCR using primers specific to the C-terminal ATP-binding region of msrA (75) . None of the strains ap- (Tables 1 and 2 ). Additional studies using an msrA probe (data not shown) substantiated the results obtained with the msrAspecific PCR primers. Thus, it appears that the efflux determinant(s) in S. pyogenes and S. pneumoniae is distinguishable from the efflux system in staphylococci bearing the MS phenotype.
DISCUSSION
We found that recent clinical isolates of erythromycin-resistant S. pneumoniae and S. pyogenes are predominantly resistant to 14-and 15-membered macrolides, a resistance phenotype known as M. This is contrary to earlier reports in which the mechanism of erythromycin resistance in streptococci was confined to MLS B resistance (29, 30, 36, 66, 72) . Although other studies have described streptococcal strains that appear to bear the M phenotype (15, 48, 58, 62-64, 67, 77) , this is the first report that provides a mechanism for the novel resistance phenotype.
Using PCR analysis, we were able to show that none of the S. pyogenes and S. pneumoniae strains with an M phenotype contain an erm determinant. Further, ribosomes isolated from a pneumococcal strain with an M phenotype proved to be fully sensitive to erythromycin and azithromycin. Several strains were characterized for their ability to take up radiolabeled erythromycin. The M strains appear to have an efflux pump, as discerned by the reduced uptake of [ 14 C]erythromycin in the absence of CCCP or arsenate. The putative efflux pump appears to be distinct from the msr-stp-smp pump described for staphylococci (37, (59) (60) (61) 73) . To our knowledge, this is the first report describing a macrolide efflux pump in streptococci.
The M phenotype is not found in a single geographical location (Tables 1 and 2) (15, 24, 48, 58, 62-64, 67, 77) . Even recent S. pneumoniae isolates from South Africa have the M phenotype, whereas 10 isolates from 1978 were all found to contain an ermB methylase (data not shown and reference 29). Thus far, we have found a 100% correlation between the M phenotype and erythromycin resistance mediated by a non-erm determinant. Our results are consistent with a putative efflux mechanism for strains with an M phenotype.
Currently, the primary set of antibiotics to be tested by clinical laboratories as recommended by the National Committee for Clinical Laboratory Standards for streptococci (47) does not include lincosamides (i.e., clindamycin) or streptogramin B, primarily because resistance to erythromycin in the past has signaled cross-resistance to these antibiotics. However, results from this epidemiological survey and others (23, 48) may well have an impact on these recommendations, since a streptococcal strain with an M phenotype remains susceptible to clindamycin and streptogramin B. The value in testing these antibiotics as part of the primary evaluation could be especially meaningful in cases in which S. pneumoniae has been recovered from patients with life-threatening infections (e.g., meningitis and bacteremia [44] ). As regards bacteremia, it is noteworthy that reports of multidrug-resistant pneumococci of VOL. 40, 1996 MACROLIDE EFFLUX IN STREPTOCOCCI 1821
on June 22, 2017 by guest http://aac.asm.org/ diverse serotypes are appearing worldwide (2, 11, 29, 44, 70, 74) . It is important that the clinician be outfitted with a full armamentarium for treating these dangerous infections. Further, Nelson et al. (48) and McCracken (44) have suggested that a clinical trial in the United States to evaluate clindamycin as a treatment for middle ear and sinus infections caused by S. pneumoniae strains resistant to other oral antibiotics may be rational; a trial to evaluate clindamycin for use in treatment of penicillin-tolerant, macrolide-resistant S. pyogenes might also prove useful. Recently, clindamycin therapy was reported to be successful in the treatment of a child with recurrent pneumococcal sepsis caused by an intermediately penicillin-resistant strain (65) . A recent evaluation of clindamycin to treat experimental meningitis caused by penicillin-and cephalosporinresistant S. pneumoniae was also reported (56) . Because of the poor clinical response to Haemophilus influenzae-mediated otitis media (20) , it is unlikely that empirical clindamycin use will be advised for patients with otitis media, however. Evaluation of the novelty of the putative macrolide efflux determinant(s) in S. pyogenes and S. pneumoniae awaits the cloning, sequencing, and functional analysis of the requisite genes. The determination of the substrate specificity and the appropriate classification of the efflux superfamily (major facilitator, resistance-nodulation-division, staphylococcal multidrug resistance, or ATP-binding cassette [41, 49] ) will also be interesting.
